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SUMMARY
Psoriasis is a T cell-mediated in¯ammatory skin disease that has been associated with infections by
group A b-haemolytic streptococci. In a previous study of patients with active psoriasis we demon-
strated an increased frequency of circulating Th1-like cells that responded to 20 amino acid (aa)
streptococcal M-peptides sharing sequences with human keratin. These cells disappeared after
ultraviolet B (UVB)-induced clinical remission. Using T cells from the blood of 17 psoriatic patients
and 17 healthy controls we have now compared the numbers of interferon-gamma (IFN-g)-producing
cells induced by seven 18±20 aa keratin peptides and ®ve corresponding M-peptides. The most frequent
and strongest responses were observed to a peptide from keratin 17 that shares ALEEAN sequence with
M-protein. The responses to this peptide were stronger than to the corresponding M-peptide containing
the ALEEAN sequence. After UVB treatment T cell responses to all the M- and keratin peptides were
abolished, while responses to the positive control antigen streptokinase/streptodornase (SK/SD) were
not affected. These ®ndings are consistent with the notion that aa sequences which keratin has in
common with M-protein may be a major target for autoreactive T cells in psoriasis.
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INTRODUCTION
Psoriasis is an in¯ammatory skin disease that affects about 2% of
Western populations. The characteristic lesions are erythematous
scaling plaques, which most frequently begin in the scalp, but
extensor surfaces of elbows and knees and buttocks are also
commonly affected.
Hyperproliferation of keratinocytes is a characteristic feature
of psoriatic epidermis and is associated with an altered programme
of keratinocyte differentiation. There is an increased expression of
keratin 14 [1] and a novel suprabasal expression of the hyperpro-
liferative keratins 6 and 16 with a corresponding reduction of
keratins 1 and 10, which are expressed suprabasally in normal skin
[2]. In contrast to normal skin, keratin 17 is expressed in suprabasal
keratinocytes in psoriatic lesions [3].
It has been demonstrated that epidermal in®ltration and activa-
tion of CD4 T cells coincides with the onset of psoriatic lesions
[4] and it was postulated that T cells play a key role in the
pathogenesis of the disease [5]. The evidence supporting this
theory is now compelling. Thus, a marked clinical improvement
has been achieved by treatment of patients with cyclosporin A [6],
anti-CD4 MoAbs [7] or administration of low-dose IL-2 linked to
diphtheria toxin [8]. Furthermore, activated autologous CD4 T
cell lines can induce characteristic psoriatic plaques in uninvolved
psoriatic skin, transplanted on mice with severe combined
immunode®ciency (SCID) [9±11]. In this model the psoriatic
lesions can be maintained by injection of T cells obtained from
psoriatic skin but not by T cells from the blood of psoriatic patients
[12]. No evidence has been reported that antibodies or immune
complexes contribute signi®cantly to the pathogenesis of psoriasis.
The onset of acute psoriasis is frequently associated with throat
infections by group A b-haemolytic streptococci [13±15], but the
effect of such infections on chronic psoriasis has not been ade-
quately documented. Streptococcal M-protein consists of ®brillar
a-helical coiled coil dimers that protrude from the surface of the
bacteria [16]. Keratin shares this structure with M-protein and an
extensive amino acid homology has been reported between protein
M6 and 50-kD (K14) type I human epidermal keratin [17].
It has been postulated that cross-reactions between M-proteins
and human epidermal keratin may play a role in the pathogenesis
of psoriasis [18]. Epidermal cells, from psoriatic patients, stimulate
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autologous peripheral blood mononuclear cells (PBMC) [19], and
recently it has been reported that dendritic cells from lesional
psoriatic skin are more effective stimulators of proliferation by
autologous blood T cells than dendritic cells derived from psoriatic
blood or normal skin [20].
We have previously reported that T cells from the blood of
patients with active chronic psoriasis respond by interferon-gamma
(IFN-g) production to 20 aa peptides [21] from the conserved C-
terminal part of the streptococcal M6 protein [22], sharing regions
of 5±6 aa with keratin. T cells from healthy controls or patients
with atopic dermatitis showed minimal or no responses to these
peptides. The reactive T cells could no longer be detected in the
blood of the psoriatic patients after ultraviolet B (UVB)-induced
remission [21].
In this study we compared T cell responses of psoriatic patients
and healthy controls to 18±20 aa keratin peptides and the corre-
sponding M-peptides used in the previous study. These two types
of peptides share regions of ®ve to six aa but contain different aa
that ¯ank the shared sequences. The T cell responses of the patients
were also monitored during UVB treatment.
SUBJECTS AND METHODS
Study subjects; clinical evaluation and treatment of the patients
The study was approved by the Ethical Committee of the National
University Hospital. Seventeen patients with active, untreated
plaque type psoriasis and 17 healthy individuals of comparable
age and sex were recruited for the study. Nine of the psoriatic
patients were also tested after 2 and 4 weeks of treatment, which
consisted of daily UVB exposure combined with bathing in a
geothermal lagoon for 2 h a day, 6 days a week for 4 weeks. This
has shown to be an effective treatment for psoriasis [23]. Disease
severity was evaluated by the Psoriasis Area and Severity Index
(PASI) before and on a weekly basis during the treatment [24].
Initially, throat swabs were obtained from the study participants
and cultured for b-haemolytic streptococci.
Antigens and identi®cation of shared sequences
M-protein was isolated from Streptococcus pyogenes serotype 6
(Public Health Laboratory Services, London, UK) according to
Pruksakorn et al. [25] as described [21]. Streptokinase/streptodor-
nase (SK/SD) was purchased from Behringwerke AG (Marburg,
Germany).
Three different ®ve to six aa sequences from the conserved C-
terminal part of M-proteins of the serotypes 5, 6, 12 and 24 (M6,
M5, M12 and M24) [22,25], which are shared with epidermal
keratins, had previously been identi®ed by multiple alignment
construction and analysis workbench (MACAW) program
(NCBI, Bethesda, MD) [21]. The M- and keratin peptides used
in this study and shown in Table 1 [21] were synthesized by the `tea
bag' method [26]. M- and keratin peptides sharing the same
sequence are identi®ed by the same numbers. An M-peptide not
sharing sequences with keratins was used as a negative control
(159-M, Table 1). The purity of the peptides was checked by high
performance liquid chromatography (HPLC).
Isolation of T lymphocytes
PBMC were isolated from 60 ml of heparinized blood by Ficoll±
Hypaque (Sigma, St Louis, MO) centrifugation [27]. Monocytes
were isolated from PBMC by plastic adherence at 378C for 1 h
in tissue culture media (TCM), RPMI 1640 (GIBCO BRL, Life
Technologies, Paisley, UK) with 2 mM glutamine (GIBCO), 100 U/
ml penicillin/100 mg streptomycin (GIBCO) supplemented with 4%
human serum albumin (HSA; Pharmacia, Copenhagen, Denmark).
The monocytes were subsequently used as antigen-presenting
cells. The PBMC were incubated with carbonyl-iron at 378C for
30 min and neutrophils removed by magnetic attraction. The
lymphocytes were washed and resuspended in TCM supplemented
with 0´2% HSA. T cells were isolated by rosetting with sheep
erythrocytes treated with neuraminidase (Sigma). They were
separated from non-rosetting cells by Ficoll±Hypaque (Sigma)
centrifugation and the sheep erythrocytes lysed with sterile
distilled H2O for 35 s [28].
T cell stimulation and ELISPOT assay
Puri®ed T cells were washed and adjusted to 1 ´ 106 cells/ml in
TCM with 10% heat-inactivated human AB serum and 5 ´ 104
autologous monocytes/ml (5%) were added. The cells were then
prestimulated with optimal concentrations of M6-protein (5´0 mg/
ml), SK/SD (200/50 U/ml), M-peptides or keratin peptides (2´5 mg/
ml) in tubes at 378C and humidi®ed 5% CO2 for 5 h. ELISPOT
assay [29] was used to determine the frequency of cytokine-
producing cells, essentially as described [30,31]. Nitrocellulose-
bottomed 96-well Millititer HA plates (Millipore Co., Bedford,
MA) were coated with 15 mg/ml of MoAbs to IFN-g (1-D1K)
(Mabtech AB, Stockholm, Sweden) at 48C for 5 h and unbound
antibodies removed by washing. The prestimulated T cells (105 in
150 ml per well) were transferred to the antibody-coated wells and
the plates incubated at 378C and humidi®ed 5% CO2 for 3 days.
The cells were then removed and biotin-conjugated MoAb
(Mabtech) to IFN-g (1 mg/ml) was added and the plates were
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Table 1. Sequences of the keratin peptides and the
corresponding M-peptides
Peptides* Peptide sequences²
145-M LRRDLDASREAKKQVEKALE
145-K17 LRRVLDELTLARTDLEMQIE
145-K10 LRRVLDELTLTKADLEMQIE
146-M AKKQVEKALEEANSKLAALE
146-M49 AKKKVEADLAEANSKLQALE
146-K17 SYLDKVRALEEANADLEVK
146-K9 SYLDKVQALEEANNDLENKI
149-M KLTEKEKAELQAKLEAEAKA
149-K7 QAEIDNIKNQRAKLEAAIAE
150-M QAKLEAEAKALKEQLAKQAE
150-K7 RAKLEAAIAEAEECGELALQ
150-K18 KVKLEAEIATYRRLLEDG
159-M MATAGVAAVVKRKEEN
*Peptides sharing sequences are identi®ed by
the same number followed by M for M-peptide
and a number for the serotype or K for keratin
peptide and number for the keratin type.
²All peptides are 20 aa long except for 146-
K17 (19 aa), 150-K18 (18 aa) and the control
peptide 159-M (16 aa) that does not share
sequences with keratin.
incubated for 3 h, followed by incubation with 1 mg/ml strepavidin-
alkaline phosphatase (Mabtech) for 1 h. The reaction was devel-
oped by 5-bromo-4-chloro-3-indolyl-phosphate/nitroblue tetrazo-
lium substrate solution (BioRad Labs, Hercules, CA) for about 1 h,
the plates were dried and blue spots counted using a dissection
microscope, one spot representing cytokine production by a single
cell. Results are expressed as number of spots per 105 T cells.
Positive Th1-like response was de®ned as $ 10 IFN-g spots/105 T
cells, above the background.
Statistical analysis
Mann±Whitney rank sum test was used to compare the T cell
responses of psoriatic patients and healthy controls to different
antigens. Frequency of psoriatic patients and healthy controls
responding to one or more of the peptides was compared with
the Fisher's exact test. That test was also used to compare the
frequency of patients and controls responding to one or more of
the M-peptides and corresponding keratin peptides. The
responses of the patients' T cells to 146-K17 were compared
with the responses to 146-M, 146-K9 and 146-M49 by paired
t-test and Wilcoxon signed rank test. The Pearson's product
moment correlation test was used to analyse the relationship
between responses of individual patients to different stimuli and
PASI score.
RESULTS
Clinical ®ndings
Before treatment the PASI score of the 17 patients ranged from 3´6
to 17´2 (mean 10´4). Nine patients who were also tested during and
after the UVB treatment had a mean PASI score of 8´9 (range 3´6±
16´4) before treatment and 2´1 (range 0±5´4) after treatment.
None of the patients had any evidence of group A streptococcal
infections at the beginning of the study, but group C streptococci
were isolated from one control (no. 13).
T cell responses of untreated patients and controls
T cells from the patients and the controls were stimulated with
seven keratin peptides and ®ve M-peptides containing three
different shared sequences, and an M-peptide not sharing
sequences with keratins was used as a negative control (Table 1).
As previously observed for the M-peptides [21], no IL-4
production was detected after stimulation with the keratin peptides,
either in the patients or in the healthy controls (data not shown).
Therefore, only IFN-g-producing T cells were enumerated
throughout this study. There was no signi®cant difference between
the psoriatic patients and the controls in responses to the whole
M6 protein or to the positive control antigen SK/SD, which
elicited much stronger responses than the other antigens (data
not shown).
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Table 2. T cell responses of untreated patients and controls to streptococcal M-peptides and keratin peptides sharing sequences*²
145-M 145-K17 145-K10 146-M 146-K17 146-K9 146-M49 149-M 149-K7 150-M 150-K7 150-K18 159-M
Patients
1 ± ± ±   ± ± ± ± ± ± ± ±
2  ±  ±  ± ± ± ± ±  ± ±
3 ± ±   ± ± ± ± ± ± ± ± ±
4 ±  ± ±  ± ±  ± ± ± ± ±
5 ± ± ± ±  ± ±   ±  ± 
6 ± ± ±    ± ± ± ± ± ± ±
7 ± ± ±   ± ± ± ± ±  ± ±
8 ± ± ±   ±  ± ± ± ± ± ±
9    ±     ± ± ± ± ±
10 ± ±  ±  ± ± ± ± ± ± ± 
14 ±  ± ±   ± ±  ± ± ± ±
15 ± ±  ±  ± ± ± ± ± ± ± ±
16 ±  ±    ± ±  ± ±  
17 ± ± ± ±  ± ± ± ± ± ± ± ±
Controls
1 ± ± ± ± ±  ± ±  ± ± ± ±
2  ± ± ± ± ± ± ± ± ± ± ± ±
3   ± ± ± ± ± ± ± ± ± ± ±
7 ± ±  ± ± ± ± ±  ± ± ± ±
9  ±  ±  ± ± ± ± ± ± ± ±
10  ±  ±   ±  ± ± ± ± ±
13 ± ±  ±  ± ± ± ± ± ± ± ±
15 ± ±   ± ± ± ± ± ±  ± ±
17 ± ± ± ±  ± ± ± ± ±  ± ±
*Positive response was de®ned as $ 10 IFN-g cells/105 cells: ÿ, < 10 IFN-g cells; , 10±19 IFN-g cells; , 20±29 IFN-g cells; , 30±39
IFN-g cells; , $ 40 IFN-g cells.
²The three patients and eight controls who showed no responses are omitted from the table.
Only three patients failed to respond to all the peptides
compared with eight of the controls (Table 2). Peptide 146-K17
from keratin 17 induced strikingly stronger and more frequent
responses than any of the other peptides. Thirteen patients
responded to this peptide compared with four controls
(P 0´005), and the responses were also signi®cantly stronger in
the patients (P 0´001). Furthermore, the patients' responses to
146-K17 were signi®cantly stronger than the responses to the
corresponding 146-M peptide that also contains the ALEEAN
sequence (P 0´001) (Fig. 1). The 146-K17 also induced stronger
responses than the keratin peptide 146-K9, which contains the
ALEEAN sequence but differs in three ¯anking aa (P 0´004). It
should be noted that only two individuals responded weakly to the
146-M49 peptide (Table 2) which does not contain the complete
ALEEAN sequence, and also differs in three ¯anking aa from the
146-M peptide (Table 1).
Overall, more patients (10/17) than controls (3/17) showed a
positive response ($ 10 T cells/105 cells) to three or more peptides
(P 0´02). Furthermore, eight patients responded to one M-pep-
tide and one or more of the corresponding keratin peptides
compared to three controls (P 0´08) (Table 2).
There was no signi®cant difference between the responses of
patients and controls to the other peptides, including the control
peptide 159-M that does not share aa sequences with keratin.
The PASI scores of the patients correlated positively with their
T cell responses to peptides 145-M, 145-K17, 146-M49 and 150-
K18 (r 0´49±0´59, P 0´01±0´05). In contrast, a negative corre-
lation was strikingly observed between the PASI scores and
responses to 146-K17 (rÿ0´50, P 0´04).
T cell responses during and after the UVB treatment
The nine patients who responded with $ 15 spots/105 T cells to
two or more of the peptides before treatment were tested after 2 and
4 weeks of treatment. For comparison, three patients who initially
showed no or borderline response were tested at the end of the
treatment.
After 2 weeks of treatment the PASI score was already sig-
ni®cantly reduced and at this stage the responses to all peptides had
disappeared in six of the nine patients. Figure 2 shows the
responses of one representative patient to different peptides
during treatment.
After 4 weeks when clinical remission had generally been
obtained, eight of the nine patients did not respond to any of the
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Fig. 1. Frequency of IFN-g-producing T cells of patients (W) and controls (A) after stimulation with M- and keratin peptides sharing the
ALEEAN sequence. Peptide 146-K17 was the only peptide which elicited signi®cantly stronger responses in psoriatic patients than in healthy
controls (P 0´001). The patients' responses to this peptide were signi®cantly stronger than to the corresponding M- and keratin peptides,
146-M, 146-M49 and 146-K9 (P 0´005, 0´001 and 0´004, respectively).
Fig. 2. Frequency of IFN-g-producing T cells from patient 9 responding to
different peptides before and after 2 and 4 weeks of treatment. The
responses to all peptides had disappeared after 16 days of treatment and
before the Psoriasis Area and Severity Index (PASI) score had decreased
markedly.
peptides. The patient who still showed responses to several
peptides, in particular to 146-K17 (Fig. 3), still had a fairly high
PASI score (5´4) and was therefore treated for 1 additional week.
The two patients who did not respond to any peptides before
treatment were still unresponsive after 4 weeks. One patient who
responded weakly to two peptides (145-K10 and 146-K17) before
treatment still responded to the same peptides after 4 weeks of
treatment. The T cell responses to SK/SD were not affected by
treatment (data not shown).
DISCUSSION
We have previously demonstrated that patients with active psor-
iasis have increased frequency of circulating Th1-like cells that
respond to 20 aa streptococcal M-peptides sharing sequences with
human epidermal keratin. We now report that T cells from
psoriatic patients respond more frequently and strongly to corre-
sponding keratin peptides containing the same shared sequences
but different ¯anking aa residues. This was particularly pro-
nounced for peptide 146-K17, which is a part of keratins 14 and
17. Keratin 17, which is not expressed in normal skin except for
hair follicles, sweat and sebaceous glands and basal cells of the
interfollicular epidermis in the scalp, is over-expressed in psoriatic
epidermis [3,32]. It is interesting in this context that the scalp is the
®rst site to be affected in the majority of patients (Gudjonsson et al.,
unpublished).
Injection of IFN-g can induce psoriatic lesions [33] and this
cytokine is believed to play a key role in the pathogenesis of
psoriasis [34,35]. It has moreover been demonstrated that the
expression of keratin 17 can be induced in vitro by IFN-g
[36,37] and this is the only keratin so far reported to be
induced by this cytokine [36,38]. The expression of K17 can also
be induced by IL-6 [39], which is abundant in psoriatic lesions
[40].
Keratin 14 is expressed together with keratin 5 in normal
epidermis, but is over-expressed in psoriasis [1] and in other
hyperproliferative conditions such as wound healing, which is
also associated with epidermal in®ltration of T cells [41]. Inter-
estingly, psoriatic lesions preferentially appear at sites of wound
healing (the Koebner phenomenon).
As keratin is a cytoskeletal protein it may not be obvious how it
could act as an autoantigen. However, it has been observed in a
carefully conducted electromicroscopical study of psoriatic epi-
dermis that cytoplasmic processes of Langerhans cells can extend
into the cytoplasm of adjacent keratinocytes with frequent absence
of intervening plasma membranes at the apices of these processes
[42]. Antigen-presenting cells therefore seem to have direct access
to keratin in psoriatic epidermis, and CD8 T cells might also
recognize keratin peptides in the groves of keratinocyte MHC I
molecules.
In our study the patients responded markedly better to 146-K17
than to the corresponding 146-M. This may be due to difference in
aa ¯anking the ALEEAN sequence. It is conceivable that 146-K17
may contain a motif that binds more strongly to the human
leucocyte antigen (HLA) allotypes associated with psoriasis.
Furthermore, the whole sequence of 146-K17 is also found in
K14. Thus the over-expression of K14 and K17 may lead to
increased presentation of this epitope.
In a previous study using M-peptides, peptide 146-M contain-
ing the shared six aa ALEEAN sequence gave the strongest and the
most frequent responses in patients with chronic active psoriasis
[21]. This was con®rmed, although the difference between patients
and controls was not signi®cant in the present study (P 0´09).
This discrepancy may re¯ect disease heterogeneity or a seasonal
variation in streptococcal infections. The previous study was
carried out in mid winter when streptococcal infections are most
frequent, but the current study in the early autumn when such
infections are less common [43].
T cells from some of the participants of our study showed
pronounced spontaneous IFN-g production resulting in apparently
negative responses (Fig. 1). This may re¯ect induction of apoptosis
by antigenic stimulation of already activated cells [44]. It has been
demonstrated that activated T cells are sensitive to anti-CD3-
driven apoptosis, whereas resting cells are relatively insensitive
[45].
A signi®cant positive correlation was observed between the
PASI score and the responses to several of the peptides. However,
a striking exception was the response to 146-K17, which before
treatment correlated negatively with the PASI score. If the K17
peptide contains a dominant epidermal epitope in psoriasis, T cells
that recognize this peptide may be more actively retained and
thereby delayed in the skin and consequently less readily detected
in the circulation. Reduction in circulating CD4 T cells has
previously been reported in patients with extensive and active
psoriasis [46].
In this study a signi®cant reduction in PASI score was observed
already after 2 weeks of treatment, and clinical improvement
coincided with a signi®cant decrease in T cell responses to 146-
K17 (P 0´004) (Fig. 3). Only one patient still showed positive
responses to some peptides at 4 weeks, but as he still had a fairly
active disease his treatment was continued for an additional week.
The T cell responses to SK/SD were not affected, indicating that
the treatment did not induce systemic suppression. SK/SD was
584 A. S. Gudmundsdottir et al.
q 1999 Blackwell Science Ltd, Clinical and Experimental Immunology, 117:580±586
Fig. 3. Changes in T cell responses to 146-K17 during treatment. Before
treatment 8/9 patients responded to this peptide and there was a signi®cant
decrease in responses after about 2 weeks (P 0´004). The only patient who
responded at the end of treatment had a fairly high Psoriasis Area and
Severity Index (PASI) score (5´4) and was therefore treated for one
additional week.
used as a positive control because it is derived from streptococci,
but in contrast to M- and keratin peptide-speci®c T cells, it was
considered unlikely that SK/SD-responsive T cells would be
selectively retained in psoriatic lesions.
UVB combined with bathing in a geothermal lagoon has
previously been shown to be an effective treatment for psoriasis
[23]. It has been demonstrated that UVB induces IL-10 expression
in human keratinocytes and dermal macrophages [47,48]. Interest-
ingly, in psoriasis the cutaneous expression of IL-10 mRNA is low
compared with other in¯ammatory dermatoses, and administration
of IL-10 has a bene®cial effects on psoriatic lesions [49].
Previous studies have shown that activated T cells disappear
from the epidermis and dermis during spontaneous or treatment-
induced resolution of skin lesions [50,51]. It has been con®rmed
that T cells disappear from the epidermis of psoriasis patients
during UVB treatment and, furthermore, that T cells are 10-fold
more sensitive than keratinocytes to apoptotic effects of UVB [52].
Recirculating T cells speci®c for the M- and keratin peptides may
therefore have disappeared from the blood as a result of UVB-
induced anergy or apoptosis in the skin. It is interesting in this
context that UVB tends to induce more prolonged remissions of
psoriasis than, for example, cyclosporin A or topical steroids
(personal observation). The participants of this study had a remis-
sion that lasted over 4 months on average (range 0´5 to
> 14 months), and relapses were in some instances in the form of
guttate type psoriasis, which is closely associated with clinical
streptococcal infections.
In conclusion, our ®ndings are consistent with the possibility
that keratin 17, which is inducible by IFN-g and contains the
ALEEAN sequence, may together with keratin 14 be a major target
for autoreactive T cells in psoriasis.
ACKNOWLEDGMENTS
The authors gratefully acknowledge Asdis Jonsdottir, at the Blue Lagoon
Outpatient Clinic, for her co-operation and Jon Thrandur Steinsson and
Michael Heidenheim for clinical evaluation of the patients and follow up.
We also thank Gunnhildur Ingolfsdottir and Inga Skaftadottir for technical
assistance. This work was supported by The Research Fund of the
University of Iceland and The Icelandic Research Council.
REFERENCES
1 Wongwaisayawan H, Yoshiike T, Aikawa Y et al. Antikeratin 14
monoclonal antibody staining in psoriasis and seborrhoeic keratosis:
immuno¯uorescence and two colour FACS studies. Arch Dermatol Res
1991; 283:405±10.
2 McKay IA, Leigh IM. Altered keratinocyte growth and differentiation
in psoriasis. Clin Dermatol 1995; 13:105±14.
3 Leigh IM, Navsaria H, Purkis PE et al. Keratins (K16 and K17) as
markers of keratinocyte hyperproliferation in psoriasis in vivo and in
vitro. Br J Dermatol 1995; 133:501±11.
4 Baker BS, Swain AF, Fry L et al. Epidermal T lymphocytes and HLA-
DR expression in psoriasis. Br J Dermatol 1984; 110:555±64.
5 Valdimarsson H, Baker BS, JoÂnsdoÂttir I et al. Psoriasis: a disease of
abnormal keratinocyte proliferation induced by T lymphocytes.
Immunol Today 1986; 7:256±9.
6 Wong RL, Winslow CM, Cooper KD. The mechanisms of action of
cyclosporin A in the treatment of psoriasis. Immunol Today 1993;
14:69±74.
7 Morel P, Revillard JP, Nicolas JF et al. Anti-CD4 monoclonal antibody
therapy in severe psoriasis. J Autoimmun 1992; 5:465±77.
8 Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a
lymphocyte-selective toxin (DAB389IL-2) suggest a primary immune,
but not keratinocyte pathogenic basis. Nat Med 1995; 1:442±7.
9 Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes
induces psoriasis. J Clin Invest 1996; 98:1878±87.
10 Nickoloff BJ, Gutierrez-Steil G, Wrone-Smith T. Dermal injection of
CD4 T-cells into symptomless (PN) skin engrafted onto SCID mice
induces phenotypic conversion to a psoriatic plaque (PP) (Abstract).
J Invest Dermatol 1997; 108:539.
11 Nickoloff BJ, Wrone-Smith T. Superantigens, autoantigens, and patho-
genic T cells in psoriasis. J Invest Dermatol 1998; 110:459±60.
12 Gilhar A, David M, Ullmann Y et al. T-lymphocyte dependence of
psoriatic pathology in human psoriatic skin grafted to SCID mice.
J Invest Dermatol 1997; 109:283±8.
13 Whyte HJ, Baughman RD. Acute guttate psoriasis and streptococcal
infections. Arch Dermatol 1964; 89:350±6.
14 Norrlind R. The signi®cance of infections in the origination of psoriasis.
Acta Rheumatol Scand 1954; 1:135±44.
15 Telfer NR, Chalmers RJG, Whale K et al. The role of streptococcal
infection in the initiation of guttate psoriasis. Arch Dermatol 1992;
128:39±42.
16 Manjula BN, Trus BL, Fischetti VA. Presence of two distinct regions in
the coiled-coil structure of the streptococcal Pep M5 protein: relation-
ship to mammalian coiled-coil proteins and implications to its biologi-
cal properties. Proc Natl Acad Sci USA 1985; 82:1064±8.
17 McFadden J, Valdimarsson H, Fry L. Cross-reactivity between strepto-
coccal M surface antigen and human skin. Br J Dermatol 1991;
125:443±7.
18 Valdimarsson H, Baker BS, Jonsdottir I et al. Psoriasis: a T-cell
mediated autoimmune disease induced by streptococcal superantigens?
Immunol Today 1995; 16:145±9.
19 Steinmuller D, Zinsmeister AR, Rogers RS. Cellular autoimmunity in
psoriasis and lichen planus. J Autoimmun 1988; 1:279±98.
20 Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal
dendritic cells in psoriasis: autostimulation of T lymphocytes and
induction of Th1 type cytokines. J Clin Invest 1994; 94:202±9.
21 Sigmundsdottir H, Sigurgeirsson B, Troye-Blomberg M et al.
Circulating T cells of patients with active psoriasis respond to strepto-
coccal M-peptides sharing sequences with human epidermal keratins.
Scand J Immunol 1997; 45:688±97.
22 Pruksakorn S, Currie B, Brandt E et al. Identi®cation of T-cell
autoepitopes that cross-react with the carboxylterminal segment
of the M protein of group A streptococci. Int Immunol 1994; 6:
1235±44.
23 Olafsson JH, Sigurgeirsson B, Palsdottir R. Psoriasis treatment: bathing
in a thermal lagoon combined with UVB, versus UVB treatment only.
Acta Derm Venerol (Stockh) 1996; 76:228±30.
24 Fredriksson T, Pettersson U. Severe psoriasisÐoral therapy with a new
retinoid. Dermatologica 1978; 157:238±44.
25 Pruksakorn S, Galbraith A, Houghten RA et al. Conserved T and B cell
epitopes on the M protein of group A streptococci. Induction of
bactericidal antibodies. J Immunol 1992; 149:2729±35.
26 Houghten RA. General method for the rapid solid-phase synthesis of
large numbers of peptides: speci®city of antigen±antibody interaction
at the level of individual amino acids. Proc Natl Acad Sci USA 1985;
82:5131±5.
27 Perlmann H, Perlmann P, Pape GR et al. Puri®cation, fractionation and
assay of antibody dependent lymphocytic effector cells (K-cells) in
human blood. Scand J Immunol 1976; 5:57±68.
28 Jonsdottir I, Dillner-Centerlind ML, Perlmann H et al. Antibody
dependent cellular cytotoxicity and mitogen responsiveness of human
peripheral blood lymphocytes differing in avidity for sheep erythro-
cytes. Scand J Immunol 1979; 10:525±33.
29 Czerkinsky C, Andersson G, Ekre HP et al. Reverse ELISPOT
assay for clonal analysis of cytokine production. I. Enumeration
of gamma-interferon secreting cells. J Immunol Methods 1988;
110:29±36.
Does keratin 17 contain an autoepitope in psoriasis? 585
q 1999 Blackwell Science Ltd, Clinical and Experimental Immunology, 117:580±586
30 Gabrielsson S, Paulie S, Rak S et al. Speci®c induction of interleukin-4-
producing cells in response to in vitro allergen stimulation in atopic
individuals. Clin Exp Allergy 1997; 27:808±15.
31 Kabilan L, Andersson G, Lolli F et al. Detection of intracellular
expression and secretion of IFN-g at the single cell level after activation
of human T cells with tetanus toxoid in vitro. Eur J Immunol 1990;
20:1085±9.
32 Wilson CL, Dean D, Lane EB et al. Keratinocyte differentiation in
psoriatic scalp: morphology and expression of epithelial keratins. Br J
Dermatol 1994; 131:191±200.
33 Fierlbeck G, Rassner G, MuÈller C. Psoriasis induced at the injection site
of recombinant interferon gamma. Arch Dermatol 1990; 126:351±5.
34 Uyemura K, Yamamura M, Fivenson DF et al. The cytokine network in
lesional and lesion-free psoriatic skin is characterized by a T-helper
type 1 cell-mediated response. J Invest Dermatol 1993; 101:701±5.
35 Prinz JC, Grob B, Vollmer S et al. T cell clones from psoriasis skin
lesions can promote keratinocyte proliferation in vitro via secreted
products. Eur J Immunol 1994; 24:593±8.
36 Flohr T, Buwitt U, Bonnekoh B et al. Interferon-g regulates expression
of a novel keratin class I gene. Eur J Immunol 1992; 22:975±9.
37 Troyanovsky SM, Leube RE, Franke WW. Characterization of the
human gene encoding cytokeratin 17 and its expression pattern. Eur J
Cell Biol 1992; 59:127±37.
38 Vogel U, Denecke B, Troyanovsky SM et al. Transcriptional activation
of psoriasis-associated cytokeratin K17 by interferon-g. Eur J Biochem
1995; 227:143±9.
39 Komine M, Freedberg IM, Blumenberg M. Regulation of epidermal
expression of keratin 17 in in¯ammatory skin diseases. J Invest
Dermatol 1996; 107:569±75.
40 Grossman RM, Krueger J, Yourish D et al. Interleukin-6 is expressed in
high levels in psoriatic skin and stimulates proliferation of cultured
human keratinocytes. Proc Natl Acad Sci USA 1989; 86:6367±71.
41 Morhenn VB. Keratinocyte proliferation in wound healing and skin
diseases. Immunol Today 1988; 9:104±7.
42 Heng MC, Kloss SG. Cell interactions in psoriasis. Arch Dermatol
1985; 121:881±7.
43 Gunnlaugsson S, Kristinsson KG, Steingrimsson O. Results of cultures
and serotyping of S. pyrogenes 1986±93. Icelandic Med J 1995;
81:728±32.
44 Green DR, Scott DW. Activation-induced apoptosis in lymphocytes.
Curr Opin Immunol 1994; 6:476±87.
45 Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven
death (apoptosis) in activated but not resting peripheral blood T cells. J
Immunol 1993; 150:4338±45.
46 Baker BS, Swain AF, Valdimarsson H et al. T-cell subpopulations in
the blood and skin of patients with psoriasis. Br J Dermatol 1984;
110:37±44.
47 Kang K, Gilliam AC, Chen G et al. In human skin, UVB initiates early
induction of IL-10 over IL-12 preferentially in the expanding
dermal monocytic/macrophagic population. J Invest Dermatol 1998;
111:31±38.
48 Enk CD, Sredni D, Blauvelt A et al. Induction of IL-10 gene expression
in human keratinocytes by UVB exposure in vivo and in vitro. J
Immunol 1995; 154:4851±6.
49 Asadullah K, Sterry W, Stephanek K et al. IL-10 is a key cytokine in
psoriasis: proof of principle by IL-10 therapy: a new therapeutic
approach. J Clin Invest 1998; 101:783±94.
50 Baker BS, Grif®ths CEM, Lambert S et al. The effects of cyclosporin A
on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J
Dermatol 1987; 116:503±10.
51 Baker BS, Swain AF, Grif®ths CEM et al. The effects of
topical treatment with steroids or dithranol on epidermal T
lymphocytes and dendritic cells in psoriasis. Scand J Immunol 1985;
22:471±7.
52 Krueger JG, Wolfe JT, Nabeya RT et al. Successful ultraviolet B
treatment of psoriasis is accompanied by a reversal of keratinocyte
pathology and by selective depletion of intraepidermal T-cells. J Exp
Med 1995; 182:2057±68.
586 A. S. Gudmundsdottir et al.
q 1999 Blackwell Science Ltd, Clinical and Experimental Immunology, 117:580±586
